Bafna Pharmaceuticals (BAFNAPH) Stock Overview
Manufactures and sells finished pharmaceutical formulations in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BAFNAPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bafna Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹165.01 |
| 52 Week High | ₹202.06 |
| 52 Week Low | ₹69.00 |
| Beta | 0.29 |
| 1 Month Change | 0.78% |
| 3 Month Change | 3.16% |
| 1 Year Change | 106.08% |
| 3 Year Change | 61.85% |
| 5 Year Change | -3.95% |
| Change since IPO | 3,487.17% |
Recent News & Updates
Does Bafna Pharmaceuticals (NSE:BAFNAPH) Have A Healthy Balance Sheet?
Dec 24
Bafna Pharmaceuticals Limited (NSE:BAFNAPH) Stock Rockets 26% But Many Are Still Ignoring The Company
Nov 17Recent updates
Does Bafna Pharmaceuticals (NSE:BAFNAPH) Have A Healthy Balance Sheet?
Dec 24Bafna Pharmaceuticals Limited (NSE:BAFNAPH) Stock Rockets 26% But Many Are Still Ignoring The Company
Nov 17Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Shares Leap 65% Yet They're Still Not Telling The Full Story
Oct 03Market Might Still Lack Some Conviction On Bafna Pharmaceuticals Limited (NSE:BAFNAPH) Even After 29% Share Price Boost
Aug 19We Think Bafna Pharmaceuticals (NSE:BAFNAPH) Can Stay On Top Of Its Debt
Aug 14There's Reason For Concern Over Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Price
Jul 01Investors Don't See Light At End Of Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Tunnel
Jul 03We Think Bafna Pharmaceuticals (NSE:BAFNAPH) Can Stay On Top Of Its Debt
Aug 15Optimistic Investors Push Bafna Pharmaceuticals Limited (NSE:BAFNAPH) Shares Up 27% But Growth Is Lacking
Feb 13The Strong Earnings Posted By Bafna Pharmaceuticals (NSE:BAFNAPH) Are A Good Indication Of The Strength Of The Business
Nov 19Do Its Financials Have Any Role To Play In Driving Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Stock Up Recently?
Dec 10Shareholder Returns
| BAFNAPH | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 16.9% | 0.9% | 1.4% |
| 1Y | 106.1% | -3.1% | 2.7% |
Return vs Industry: BAFNAPH exceeded the Indian Pharmaceuticals industry which returned -3.1% over the past year.
Return vs Market: BAFNAPH exceeded the Indian Market which returned 2.7% over the past year.
Price Volatility
| BAFNAPH volatility | |
|---|---|
| BAFNAPH Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: BAFNAPH has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: BAFNAPH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 406 | Bansilal Mahaveer Bafna | www.bafnapharma.com |
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.
Bafna Pharmaceuticals Limited Fundamentals Summary
| BAFNAPH fundamental statistics | |
|---|---|
| Market cap | ₹3.90b |
| Earnings (TTM) | ₹87.72m |
| Revenue (TTM) | ₹1.42b |
Is BAFNAPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAFNAPH income statement (TTM) | |
|---|---|
| Revenue | ₹1.42b |
| Cost of Revenue | ₹960.66m |
| Gross Profit | ₹462.74m |
| Other Expenses | ₹375.02m |
| Earnings | ₹87.72m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.71 |
| Gross Margin | 32.51% |
| Net Profit Margin | 6.16% |
| Debt/Equity Ratio | 35.5% |
How did BAFNAPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/23 23:00 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bafna Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.